ArticleFrontiers in neurology2025
Clinical outcomes in spontaneous subarachnoid hemorrhage after introduction of continuous intra-arterial vasospasmolysis for treatment of refractory delayed cerebral ischemia.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with refractory delayed cerebral ischemia (DCI) after spontaneous subarachnoid hemorrhage (SAH), endovascular therapy of cerebral vasospasms is a treatment option. In our center, continuous intra-arterial vasospasmolysis with nimodipine (ciaN) has been introduced as the standard endovascular therapy for cerebral vasospasms since 2016. This study investigated the outcomes of SAH patients before and after introduction of ciaN. Methods: Data pertaining to all patients treated for SAH in our center between 2011 and 2021 were retrospectively recorded. Results: 145 patients before (pre-ciaN group) and 147 after (ciaN group) introduction of ciaN met the inclusion criteria. 36 patients in the pre-ciaN group and 51 in the ciaN group received endovascular vasospasm treatment. At discharge, outcomes tended to improve in the ciaN group. After 6 months, there was a significantly improved outcome in the ciaN group (mRS 0-2, Fisher's exact test). After propensity score matching, there were no significant differences between the pre-ciaN and ciaN groups in the subgroups of patients without endovascular vasospasm treatments. Conversely, in the subgroups of patients who had received endovascular vasospasm treatments, there was a significantly improved outcome at discharge and after 6 months, and a significant reduction of DCI-associated infarctions. Conclusion: Outcome after spontaneous subarachnoid hemorrhage has improved since the introduction of ciaN in our center. Our data indicate a contribution of the changes in treatment standard for endovascular vasospasm therapies from angioplasties to ciaN. Prospective studies are needed to compare the effect of ciaN in DCI with standard medical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.